<SEC-DOCUMENT>0001628280-23-034354.txt : 20231013
<SEC-HEADER>0001628280-23-034354.hdr.sgml : 20231013
<ACCEPTANCE-DATETIME>20231013142052
ACCESSION NUMBER:		0001628280-23-034354
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20231012
FILED AS OF DATE:		20231013
DATE AS OF CHANGE:		20231013

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYBIN INC.
		CENTRAL INDEX KEY:			0001833141
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40673
		FILM NUMBER:		231324776

	BUSINESS ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
		BUSINESS PHONE:		(908) 764-8385

	MAIL ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>cybininc-form6xk10x12x2023.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1e3d243bed3f4248ad674d282191f8c5_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Washington, D.C. 20549</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Form 6-K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the month of October, 2023.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commission File Number&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">001-40673</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Cybin Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Exact Name of Registrant as Specified in Charter)<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Address of principal executive offices) </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form 20-F  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:115%">&#9633;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  Form 40-F &#8864;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURE</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:5.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CYBIN INC.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Registrant)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 13, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#47;s&#47; Doug Drysdale&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Doug Drysdale</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">EXHIBIT INDEX</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="cybnpressreleaseannouncing.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">News Release dated October 12, 2023</a></font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cybnpressreleaseannouncing.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id3a927b39b5e4cf195d3676153c4ec4f_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:1.72pt;padding-right:1.72pt;text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:120px;margin-bottom:5pt;vertical-align:text-bottom;width:206px"></div><div style="padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:100%">Cybin Announces Results of Annual and Special Meeting of Shareholders</font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:123%">TORONTO, CANADA </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:123%">&#8211; October 12, 2023 &#8211; </font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:123%;text-decoration:underline">Cybin Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:123%"> (</font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:123%">NYSE AMERICAN&#58;CYBN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:123%">) (</font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:123%">NEO&#58;CYBN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:123%">) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:123%">Cybin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:123%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:123%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:123%">&#8221;), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce the voting results for each of the matters presented at the Company&#8217;s annual and special meeting of shareholders held on October 12, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:123%">Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:123%">&#8221;). There were 66 shareholders represented in person or by proxy at the Meeting holding 91,903,025 common shares, representing 39.16% of Cybin&#8217;s total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.84pt">Acquisition Resolution</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The acquisition of Small Pharma Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Small Pharma</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), by way of a proposed plan of arrangement under the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Business Corporations Act </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(British Columbia), pursuant to the terms and subject to the conditions of the arrangement agreement between Cybin and Small Pharma, dated August 28, 2023, was approved. Voting results are set out below&#58;</font></div><div style="padding-left:30.06pt;padding-right:30.06pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.519%"><tr><td style="width:1.0%"></td><td style="width:21.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Votes For</font></td><td colspan="6" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Votes Against</font></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">#</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">#</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">43,199,295</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">99.410</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">256,200</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.590</font></td></tr></table></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.84pt">Appointment of Auditor</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Zeifmans LLP was appointed auditor of Cybin until the next annual meeting of shareholders at renumeration to be fixed by the directors of Cybin. Voting results are set out below&#58;</font></div><div style="padding-left:30.06pt;padding-right:30.06pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.519%"><tr><td style="width:1.0%"></td><td style="width:21.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Votes For</font></td><td colspan="6" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Votes Withheld</font></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">#</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">#</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">91,252,133</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">99.292</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">650,891</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.708</font></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.84pt">Number of Directors</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The special resolution to set the number of directors of Cybin at six was approved by at least two-thirds of the votes casts by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:30.06pt;padding-right:30.06pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.519%"><tr><td style="width:1.0%"></td><td style="width:21.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Votes For</font></td><td colspan="6" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Votes Against</font></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">#</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">#</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">90,712,567</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">98.705</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,190,458</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.295</font></td></tr></table></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.84pt">Election of Directors</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each of the nominees for election as director listed in Cybin&#8217;s management information circular dated September 13, 2023 were elected as directors of Cybin for the ensuing year or until their successors are elected or appointed. Voting results are set out below&#58;</font></div><div style="padding-left:10.62pt;padding-right:10.62pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.346%"><tr><td style="width:1.0%"></td><td style="width:20.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Votes For</font></td><td colspan="6" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Votes Withheld</font></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">#</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">#</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Theresa Firestone</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">42,976,922</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">98.899</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">478,573</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.101</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Grant Froese</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">43,022,128</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">99.003</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">433,368</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.997</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Paul Glavine</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">43,012,466</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">98.980</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">443,030</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.020</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Eric Hoskins</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">42,906,846</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">98.737</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">548,649</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.263</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mark Lawson</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">42,971,117</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">98.885</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">484,379</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.115</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Eric So</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">39,668,729</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">91.286</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,786,767</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.18pt;text-align:center;text-indent:-0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.714</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">About Cybin</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin&#8217;s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland.  For company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Cautionary Notes and Forward-Looking Statements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as &#8220;may&#8221;, &#8220;should&#8221;, &#8220;could&#8221;, &#8220;intend&#8221;, &#8220;estimate&#8221;, &#8220;plan&#8221;, &#8220;anticipate&#8221;, &#8220;expect&#8221;, &#8220;believe&#8221; or &#8220;continue&#8221;, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company&#8217;s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Any forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include&#58; implications of the spread of COVID-19 on the Company's operations&#59; fluctuations in general macroeconomic conditions&#59; fluctuations in securities markets&#59; expectations regarding the size of the psychedelics market&#59; the ability of the Company to successfully achieve its business objectives&#59; plans for growth&#59; political, social and environmental uncertainties&#59; employee relations&#59; the presence of laws and regulations that may impose restrictions in the markets where the Company operates&#59; and the risk factors set out in each of the Company's management's discussion and analysis for the three months ended June 30, 2023, and the Company&#8217;s annual information form for the year ended March 31, 2023, which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin makes no medical, treatment or health benefit claims about Cybin&#8217;s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin&#8217;s performance and operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">Neither Cboe Canada, operating as the Neo Exchange Inc., nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.</font></div><div style="text-align:justify"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%"></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Investor &#38; Media Contact&#58;&#160;</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Gabriel Fahel</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Chief Legal Officer</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin Inc.</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1-866-292-4601</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">irteam&#64;cybin.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> &#8211; or &#8211; </font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">media&#64;cybin.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@   <P   $," (   #&41%E   TYTE$051X7NV=
M=U<;R?+W?^__W\?+VEY[D\->$TRPP8"QL3$H@A)!@2 $D@ A1)2$(D^+N:LK
M5VMF.HVD&=7G?,^>M:VIR34=JJO^[P%!$ 2QC/^#?X$@"(*H YTL@B"(A:"3
M11 $L1!TL@C2:ZYSF4PLD(ZN7Z3WFXT&_&?$6:"319">4L@D=[V?@Y_>!&9?
M15<^Y YC\!>(LT GBR ]XNKL.+(TZGKW_X#.#K;A3Q$'@4X607K!Z=XF[5XU
M>2>>-1MUN 'B%-#)(HCEI")NVK=VJI!)PFT0IX!.%D$LI-EL)-P+M%<%(EX8
M;HDX!72R"&(AX<5WM$NEM;^^#+=$G (Z602QBCW?%]J?=M7!QG>X,>(4T,DB
MB"7DCQ*T,]43#A<X&'2R"**>NT*.]J0&.MW;A"80IX!.%D$4<U^\<8^-T)[4
M0#?G66@%<0KH9!%$,8&Y5[0;-9!G?*11KT$KB%- )XL@*DD&?]!NU%B;7\:A
M%<1!H)-%$&74:Q7:AYJ*^&5H"'$0Z&011!G;WR9I'VHJG/5R-NAD$40-Z>@&
M[4!95+J^@+80!X%.%D$44"G?T=Z318'9OZ$MQ%F@DT40!6PMOZ<=*(MP&8+C
M02>+(++DC_=H[\FHTDT!FD.<!3I9!)&B7JVX1Y_0WI-%I/T+S2&. YTL'^7;
MRXOT_NG>YF%X;<_W);[V*;HR0Q1;FR-_/-KTD'\J9 [NBS=P2\2A9.,AVGLR
MBCPJT!SB.-#)FE"O52Y/4JF(:^?[],:'/^GW1$_AQ7>'H=6KTR-H$7$0S6;3
M-_D;??=91#:$YA G@DZV.Z7K0B86($U4X5>HK<#L*]*\;3:Q**D#,2UY8"#R
MY8;F$">"3O9_-!N-F_/L22),&JWT*R$IT@HF7KM\=PWWBMB62NF6OM'LJI:+
MT"+B1-#)MJB4[M([_O69/^@W0;E.=B-P]X@]V5P:H^\OH_;\7Z YQ*$,NY,E
M3===SR)O8CI)Q=;FZM4*/!3$5ESG,O2=91=&;@T/P^MD;_(GL=59^NGOC=9G
M?B<' (\)L0^A^3?T;664?^H%-(<XEV%TLJ0-$OWQD7[T>Z_\\1X\.,0.7)T>
MT7>370<;WZ!%Q+D,EY/-'^UN?AFG'_H^"H=H[<C65\%%M"V-/JG=EZ%%Q+D,
MBY.]SJ6E7@PKE8T'X>$B TSQ*D_?1';M>I>@1<31.-_)UFO5A&>1?M8'2F<'
MV_"XD4%E^]L4?0?95;ZYA!811^-P)YL_2O0F,$M>N#;,%I1N"O2]8]?FTABT
MB#@=QSK9J[/CV.I S&XQRCTV@G%=@X_DH--U+@,M(D['F4XV&5BAG^_!5WCQ
M'3P39)"X/DO3=XU=D<]X?X<1ISG9VXNS\,(_]/-M%Z7"N)Y]<(E\'J5O&;LP
MY]9PXB@GF][QTT^V[717R,$30P: F_P)?;/8M3[S.[2(# =.<;+-9GQMCGZR
M[:B-#W_"LT,&@/C:)_IFL6O7LP@M(L.!$YQL[C"V\?$O^K&VK_;7E^%)(GVE
M4:]YQG^E[Q2[L(,RM-C>R1X$OM,/M -4*=W"4T7Z1WIGG;Y'[-K\,@XM(D.#
MO9WLH*V152@L8CI0^":?T_>(71@$/<S8U<G6*F7)J=X!EWOLET:C#D\;Z0>Y
MPQA]@]B%4UY#CBV=;"%SX)]^23_-/=#ZS!^QM;ED\$<N&;W.9>Z+-Y72'=%=
M(7>>BB<#*SO?IST33^D-!700^ [/'.D'DB/^Y%&!%I%APGY.]C"T1C_'/1#Q
MK:TXQV83'A!%];ZD:J08*Y3T'?+MI.\+N[ 9B]C,R:;"+OHYMEK$O9:N+^"A
MF'&2"-.F>'486H5VD=X2_/2:OB_LRL9#T"(R9-C)R9)..OT06ZK@W.N+]#X\
M#F:R\2!MDTO>B6=-AK8S8A&2"Q \X[\VZC5H%!DR;.-D=[V?Z8?84BF9WX])
M+Y'('^]"HTBOD*R@01Y::!$9/FS@9&OWY:UEJ=1'O HO_'.;/X7'(01IATKF
M6L2L,?VB4KRE;P>7,'(+>;"%DY6I6"<@Y:V/_-$NO1<N"8P((_*<[FW2]X)=
M@8]_08O(4#+H3E8R?2>OTM$-> 32-!IU]^@3>E_L.MKT0*.(]807_T/?"W:=
M[F]!B\A0,M!.=NOK!/WL6J?S5 (>@2*"GZ0:X]$?'Z%%Q&+N+L_I&\$NS_A(
ML]F 1I&A9$"=;*->WUZ>I)]=ZW22",.#4(=DV&QP[C6TB%A,W"65<RL5P;S
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MII))7L'59&NK<Q1R?WV9_L& R/O^6;/1Z#A=5K:6W]/6]"0S!"R<7I)W&<C
MPNUD>6,>>27\T PGE>(M?0U-I20HAV;7LTCO2XEB:W-P9VR(-?.)M,A_\BDR
MCI\?!(DEL^=JR8KW>YK-]9D_:(,L(L\VM,;)??'FZO3X9#=\O.5-!G\<!+ZG
MPFN96""7C-[F3Q46A"Y>Y:]S:?)5Z#H$Q^UD(Y]'Z<NA4-B,Y>)@@R,VMJV3
MW0@T)(U8@YI1WHFGS:;(IU<L>"N\\ _9MI 1++G8>]4JW&LWN%YDX65![-&X
M0#*E*$A#<-__U33 SC_],N%9S!\E&J*1@L2W[OF_:+50VPHOO@/+-_B<;/GV
MDCY6M1)X7(89@<Q2])2./*F(F]Z16IFN"^B*F.O/QH/79R+39?V2P H%\B&A
M[>AI<VD,;L^&V*RC2ZCM7+HN'(;6!"8G_5,O6C4!.(,9.H?IHS\^)H,KY"X$
M9E]I?Q-WS;>;!7Q.-A.SMAXM1FYQ09XJ^AJ::E<G_%,8JR="-=V<9^&.&>!R
M)6V1Q@C]EY+R3?ZV_6V*]%@?\Z(%CS8]Y)W<_#+.N-C45+Q)9(*?7M-&]!3Y
M_ YNS\;I_A9MC47)P JTI4^U7)0/*B7>.7^T"TWKT$[;0DX0_-/MQ:EV;4/S
M;S7'S>=DHS\^T >G4 I74@X#L=59^AJ:JI!1.>5UWJMI]VR<.QZ>/9F#=2)M
M0-*:)M=<KT]*G&,N&4VX%X3'+C41]PU-&\(U?:V-GP@07?E 6V,1H[\KW13(
MYZIKSCDQ)3R+IMD7\\=[VH^UJ;E:I7Q[<48: <2]:N.\I T;7OR/Z]_V.(>3
MK=V7Z6-2*/FP\Z'B7BC\T#_]$AJ2@#Q5]"XLTIYO">[>C+.#;=I.ST1:J5RI
MD)O-YLEN1&S=A";VQBSQ!5Q)2H-SKZ$)!F0"ZEGR7@HL)&.1>_0)\=UP9_]"
M+K+V,ZT-"XZ!W+YD\,?#HY_U3K3Z*">[80XG*Y;I@UU<3R1"^E/T-315)K8!
M#8E"VHG&6?+4:OL;]R!=OT*O2,?S/)6 1\,&>;T[<ZURB7TI*O$47*V_@% X
M"FF_TZ981)J!T-;/D(^$I2N;?9._Z266U,H4M.?EM.7LI(M/3K8=D:UU%C7_
M2\Z%P\F2C@]]-*J$"Q"X(*T>[3O)I]$GJE*ND /@ZF_*2V!)@M6C6UU%&C*2
M,8CD]1:K3&KJF]K<%V_HS0TD]GJ*A;X0'896H:T.[@HY@?E>7A$WVC7&*[HR
MXWJ\R]H?M721[9%9+:-F.KK^\!A[X'HL7\3J9(63Q3$JX9Z'NT3TR1\EZ&MH
M*H$>MQY;7SE"V96(^!W>Q>QB.63%-?I$52Y4L;$@U[_AO:80/T5O:R"!B__
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M6EQ+?1$N2,<_EXR2)BKY-&XO3Y+G>VOY?7QMCC0G2;/B.I=A#^A30GK'3S\
MC"+? X6):0I9[O5RDA&IS6:C=%T@O6QR1S*Q &FR'896B5+AM>-M'[D=YZDX
MZ2FR3TSW@$:C3HZ6>'SRUI,C-$@:RP6Y#N1DR4?K9#=R<;Q'FF[P%X,'RS*-
MT/P;N)D979QLLU$WZ$>(:<^/3G98D FR9DR8S0[O5.'@3,4@?<%XN2#QL 9)
M=?7HXF0)Y'M.[T!&V)(UX/[N^JZ0XQKE&5A8V@)ZLJ)B/&G%<X7KLBQM0IQ-
M-AZD%VN$%]^1'HF AWW0<[*7V4/Z^9,1[RC&D) _WHM\_M^TR<;'OU(1]R#$
M9HM!'D'/^*_TW6>1<*I_4TC_E]Y=5W'%Y2#.YNKLF+08TM'UW&%,<JRCNY,5
M2+!H+-.\&T.(7L<D^.E-0]VX9"^YX"](UQ9YIJ$Y=3"&%O6R0BHR/'1WLM7[
MDF3B,J#8ZBS<QQ!3KU9(UYB^2FV9+NX<3&)K<_2YL(@KZE",9,!\W>1U+@,W
M0Q!INCM9POH,TX(01NU\GX8[&%:*5WG3Q38",YA]IU*\I4^$19[Q$;&A+E[(
MEY[>>UN]K]^'# FZ3I8W+8VQ,'>!QGDJP=)%,"Y:-YAL?S-JFQOH@J?PIR2M
ML-!I&!9*%%[XIU:]A[]&$!7H.MD]/W?Z= ,%/]FO::8<]A6QC,GE!H>[0HX^
M"Q;YIJR:[]*C7JNF(NZ-?Z>/_5,O6ND-FTWX.P11A*Z3Y4J&9JKUF=^;P_T<
M<]7\Z$V*$(5L?17L]R@/C&7GOGA#U)N1"F28T76R,C/%M-QC([7*\';'>'-!
M]'X9NPS%*\%ZM('95] 6@C@.72<KGP\42#+6S*;4JO?&\RVT>C#5KI:MKQ/T
M6;#H^BP-;2&(X]!UL@3_U OZQ1#6Y4D*[L#I7)T>\19H<S$GHA\0>!-QMA7]
M85(7%D&<@9&3-8[EY-79P3;<@:,16YK,F#1Z<. ="6E+;>UQ!!E8C)PL2_PV
MNRS-PS]HF&;5["K2=8"&!IMJN2B6G!LK92##@Y&39<F=SJ[AR=LM7*75TK).
M5B"<=_@V;WGB< 09$(R<;.E&Y=S7,(3*EJXOA+O/T949:&ZP$8Z-Q;55R%!A
MY&0?5"^N'=BDZ$JX.CL6ZSN['G-0V2Z..#3_ACX1%J6CZ] 6@C@7$R>K=MV7
M@T-V&/,\Z>FN< 8M#C:7)RGZ+!B%.5N1H<+$R0H'Z'25[18R,9**N.F39=?)
M;AA:''@"LW_3)\*BK:_OH2T$<30F3K;1J'LGGM&OBICB:S8+LS?E_NYZA[/
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M3M:QW-]=IR*NS2_CP;G7@=F_PPO_' 2^5\M%^#L$0:SD_P.!FI"CC7N0 P
*  !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
